X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PANACEA BIOTECH ALEMBIC PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 24.4 -20.0 - View Chart
P/BV x 6.8 2.8 243.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
ALEMBIC PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs792149 532.4%   
Low Rs44382 538.3%   
Sales per share (Unadj.) Rs167.084.1 198.5%  
Earnings per share (Unadj.) Rs38.2-18.3 -208.5%  
Cash flow per share (Unadj.) Rs42.0-6.7 -626.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.983.7 101.4%  
Shares outstanding (eoy) m188.5261.25 307.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.4 269.3%   
Avg P/E ratio x16.2-6.3 -256.4%  
P/CF ratio (eoy) x14.7-17.2 -85.3%  
Price / Book Value ratio x7.31.4 527.0%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3837,074 1,645.1%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m4,2141,449 290.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m31,4875,154 611.0%  
Other income Rs m55100 55.2%   
Total revenues Rs m31,5425,254 600.4%   
Gross profit Rs m10,060-766 -1,312.8%  
Depreciation Rs m722711 101.6%   
Interest Rs m371,503 2.4%   
Profit before tax Rs m9,356-2,881 -324.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-2-6 26.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m2,16017 12,858.3%   
Profit after tax Rs m7,194-1,121 -641.6%  
Gross profit margin %31.9-14.9 -214.9%  
Effective tax rate %23.1-0.6 -3,958.8%   
Net profit margin %22.8-21.8 -105.0%  
BALANCE SHEET DATA
Current assets Rs m15,0663,810 395.4%   
Current liabilities Rs m7,6748,365 91.7%   
Net working cap to sales %23.5-88.4 -26.6%  
Current ratio x2.00.5 431.0%  
Inventory Days Days67156 43.0%  
Debtors Days Days4167 60.4%  
Net fixed assets Rs m8,23714,480 56.9%   
Share capital Rs m37761 615.0%   
"Free" reserves Rs m15,416903 1,707.1%   
Net worth Rs m16,0055,127 312.2%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m24,59419,433 126.6%  
Interest coverage x255.2-0.9 -27,849.3%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.30.3 482.8%   
Return on assets %29.42.0 1,496.9%  
Return on equity %44.9-21.9 -205.5%  
Return on capital %58.73.6 1,613.6%  
Exports to sales %55.724.5 227.3%   
Imports to sales %10.410.2 102.4%   
Exports (fob) Rs m17,5511,264 1,388.7%   
Imports (cif) Rs m3,283525 625.6%   
Fx inflow Rs m17,8111,539 1,157.1%   
Fx outflow Rs m5,318942 564.5%   
Net fx Rs m12,493597 2,091.8%   
CASH FLOW
From Operations Rs m9,304599 1,552.7%  
From Investments Rs m-3,105-438 709.0%  
From Financial Activity Rs m-1,959-303 647.4%  
Net Cashflow Rs m4,240-141 -3,000.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.6 483.3%  
FIIs % 9.1 1.3 700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.6 58.9%  
Shareholders   49,328 10,259 480.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  ELDER PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ELDER PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS